T he good news is that oncologists have done a great job treating breast cancer. The bad news is that cardiovascular disease is emerging as the most important competing mortality risk in women with early stage breast cancer. 1 It is sobering for a cardiologist to see a patient losing the battle to heart disease after winning it against cancer. In this issue of Circulation, 2 important articles are published, adding to our understanding of heart failure as a result of chemotherapy and radiation therapy in the breast cancer survivor.
We have known since the late 1960s the relationship between anthracycline dose and left ventricular ejection fraction (LVEF) reduction and the development of the heart failure (HF) syndrome. 2 More recently, our group and others have studied the relationship of new parameters, such as global longitudinal strain and ventriculoarterial coupling, reporting on early outcomes at 6 to 12 months. [3] [4] [5] However, we have lacked data on the impact of these parameters at longer follow-ups. At the end of the day, the million dollar question is whether the change in these parameters actually impacts relevant outcomes, such as the downstream development of heart failure, increased mortality, or reduced quality of life.
The article published by Narayan et al 6 is the first to report outcomes at 3 years after comprehensive characterization of changes in left ventricular structure, function and ventriculo-arterial coupling in patients with breast cancer receiving doxorubicin or trastuzumab. The first message to take home from this study is that anthracyclines do not appear to be leaving the oncology toolkit anytime soon, having been used in 82% of the patients, either alone or in combination with trastuzumab. Interestingly, the decline in LVEF at 1 year was similar in patients receiving doxorubicin and trastuzumab alone (previously thought to be an innocent regimen) and worse in patients receiving doxorubicin and trastuzumab in combination. Although doxorubicin was associated with a persistent decline over time, a small improvement was observed with trastuzumab at 3 years.
It is important to note that the baseline LVEF and global longitudinal strain were between 1 and 2 SD below the normal reference ranges (LVEF 63+/-5, global longitudinal strain -21.5+/-4), 7, 8 likely a reflection of a population with higher cardiovascular risk as evidenced by the number of comorbidities, their requirement for antihypertensives, and the fact that most of the patients were obese.
In the doxorubicin group, no significant changes occurred in left ventricular enddiastolic volume over time, initial increases in left ventricular end-systolic volume were found, and an initial worsening of strain was present. An initial increase was seen in LV mass and relative wall thickness, possibly representing the presence of myocardial edema. Although a similar increase was observed in myocardial thickness for the doxorubicin/trastuzumab group, the behavior of the left ventricular enddiastolic volume was quite different, with an initial increase followed by a reduction at Good News, Bad News, but Not Fake News © 2017 American Heart Association, Inc.
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2 and 3 years. This finding is interesting because it goes against the previously proposed biomechanical model, where apoptosis initiated by anthracyclines and exacerbated by trastuzumab would result in LV remodeling with increasing LV diastolic volumes and a resultant reduction in LVEF. Although it is expected to see an increase in LV mass and relative wall thickness initially, it is unexpected to continue to observe it at 3 years, a point where one would expect the initial edema to have subsided allowing for the loss of myocytes to manifest as a reduction in LV mass.
To understand the findings of this study, we may need to take a look at the pediatric literature, where this phenomenon has already been described and where a continuous reduction in left ventricular end-diastolic volume, accompanied by an increase in LV wall thickness, creates the so-called Grinch syndrome, where the hearts are too small for the body size after doxorubicin treatment for acute lymphoblastic leukemia. 9 We look forward to the use of advanced technologies, such as cardiac magnetic resonance, which are better equipped to evaluate subtle differences in LV volumes and cardiac mass to hopefully corroborate the findings reported by these authors.
It is not fake news but reality that both anthracyclines and trastuzumab result in modest but persistent declines in LVEF at 3 years. We remain curious as to the long-term impact of this decline on HF symptoms, need for hospitalizations, mortality, and quality of life for these patients. The good news that we can learn from this study is that early changes in LV volumes, strain, and arterial stiffness at 4 to 6 months prognosticate subsequent LVEF changes and HF symptoms 1 to 2 years after initiation.
In addition to systemic chemotherapy and surgery, treatment of invasive breast cancer also includes chest radiation, which may independently increase the risk of cardiovascular disease and contribute to adverse outcomes in cancer survivors. 10 This issue of Circulation also brings important light to our understanding of radiation-induced heart disease. Harmful cardiovascular effects of therapeutic chest radiation, including accelerated atherosclerosis, pericardial and myocardial fibrosis, and valvulopathy, have been known for decades and have led to changes in modern radiation oncology techniques, such as lowering of total radiation dose, shielding of the myocardium, and more precise radiation delivering that avoids heart structures. 11, 12 However, the impact of new cardioprotective techniques on reduction of mean cardiac radiation dose (MCRD) has been difficult to assess, creating a gap in our understanding of potential cardiovascular consequences after contemporary radiation. Several ongoing challenges in addressing this gap are important to note: (1) an accurate estimation of MCRD requires an individual, patient-level analysis of radiotherapy treatment plans, which often are heterogeneous, reflect local radiation oncology practices, are not standardized in reporting, and are not readily available 13 ; (2) cardiovascular risk may differ even among the individuals receiving the same MCRD depending on which critical structures (eg, coronary arteries, myocardium) had been included in the affected volume 13 ; and (3) population-based studies have been necessary to account for a long time delay between injury and clinical events, but they mostly focus on myocardial infarction and valvular disease morbidity and mortality, and they often fail to identify and capture more subtle cardiovascular (CV) phenotypes. 10, 14 The good news coming from the long-term cohort studies in patients with breast cancer is that the excess risk from death of ischemic heart disease with left-sided compared with right-sided cancer has consistently declined with radiation treatment after 1979.
14 Despite this progress, the bad news is that our understanding about the actual heart radiation exposure during contemporary breast cancer treatment and the heart radiation doseassociated CV risk has not advanced much. As a consequence, no specific strategies exist for CV risk stratification, monitoring, or CV treatment during radiation, with the exception of the recommendation to use heart-doselimiting radiation techniques.
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The study by Saiki and colleagues 15 addresses several important challenges and offers novel insights in defining CV risk with radiotherapy. The authors hypothesized that increasing cardiac radiation exposure, even at doses traditionally considered to be low, may impact coronary microvasculature and lead to increased HF risk. They designed a case-control study among women, residents of Olmstead County, all of whom received contemporary radiotherapy for breast cancer initiated at the Mayo Clinic between 1998 and 2013. Access to complete medical records allowed the investigators to calculate the individual MCRDs based on the integration of the patients' chest CT image sets and individual radiotherapy plans. The odds of incident HF increased with higher calculated MCRD, even after adjustment for other risk factors, cancer side, and cancer stage, lending support to the hypothesis of a direct association between HF risk and heart radiation dose that has been lacking in previous trials. The overall MCRD was 2.5 Gy (typical total radiation dose in patients with breast cancer is ≈50 Gy); although MCRDs and HF risk were significantly higher in patients with left-sided compared with right-sided cancer, tumor laterality did not precisely reflect the differences in individual MCRD. This observation is important because it highlights that even low radiation doses (eg, radiation of internal mammary nodes in a patient with right-sided breast cancer) is associated with measurable HF risk. It is important to note that earlier studies which included women with right-sided chest radiation as controls could not have captured this risk. 14 Another unique and clinically relevant aspect of the new study is its detailed exploration of HF outcome. The authors extracted diagnostic ICD codes for HF and CV comorbidities for all patients and then performed manual chart review applying both Framingham and clinical HF criteria to identify and ascertain incident HF cases and matched controls. Interestingly, ˂20% of patients with HF also experienced ischemic events, challenging the old paradigm of epicardial coronary artery atherosclerosis as the predominant mechanism of HF in patients exposed to therapeutic breast cancer radiation. Indeed, the majority of patients had preserved or mildly reduced EF (LVEF >40%), leading the authors to propose coronary microvascular endothelial inflammation with rarefaction and fibrosis as the underlying mechanisms linking therapeutic radiation to HF with preserved ejection fraction. 15 This conceptual framework importantly acknowledges the relevance of comorbidities often seen in older patients with breast cancer and raises the hypothesis that even low doses of contemporary radiation synergize with existing subclinical myocardial disease manifest as overt HF.
What are the lessons for clinical practice? The recently published American Society of Clinical Oncology Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Adult Cancer Survivors recommends use of advanced techniques, including deep-inspiration breath holding and intensity-modulated radiotherapy to prevent cardiac dysfunction in patients receiving a total radiation dose of >30 Gy where the heart is in the radiation field. 11 The study by Saiki and colleagues 15 provides an example of successful measurement of heart exposure-reducing strategies and identifies HF with preserved ejection fraction as an important radiation-associated risk for the clinician to be aware of and for the investigators to validate in other cohorts. It also generates a hypothesis that early diagnosis and optimal treatment of hypertension and predisposing factors of HF with preserved ejection fraction may improve outcomes in breast cancer survivors exposed to therapeutic radiation. These 2 studies are important additions to our understanding of the pathophysiology of breast cancer therapeutics and radiation-induced HF, underscoring the important interplay between the treatment that the patient receives and her comorbidities.
We look forward in the years to come to long-term follow up data on the prognostic role of early detection and treatment of cancer therapeutics-related cardiac dysfunction, as well as studies evaluating the role of treatment of comorbidities, such as hypertension and hypercholesterolemia in the mitigation of radiation-induced heart disease. 
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